GLAUKOS Corp (NYSE: GKOS)

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. The company pioneered Micro Invasive Glaucoma Surgery (MIGS) with its iStent family of devices and has expanded into sustained release pharmaceuticals such as iDose TR, bio activated corneal crosslinking therapies under the iLink platform, transdermal formulations via the iLution platform, and posterior segment drug delivery implants under the Retinal XR platform. Glaukos Corp operates primarily in the United States with expanding international presence in Europe, Asia, and Latin America.

Glaukos Corp generates revenue principally from the sale of its medical devices and pharmaceutical products to eye care providers. The company's iStent family of micro scale surgical devices, the iDose TR intracameral pharmaceutical implant, and related glaucoma accessories together accounted for approximately 79% of net sales in 2024, while its iLink therapies for corneal crosslinking contributed roughly 21% of net sales in the same year. Sales are made directly to ambulatory surgery centers, hospitals, and physician private practices, with approximately 70% of 2024 net sales originating from the United States and the remaining 30% from international markets. No single customer or distributor represented more than 10% of total net sales in 2024.

The company operates through the following segment:

• Ophthalmic therapies: This segment encompasses the development and commercialization of therapies for glaucoma, corneal disorders, and retinal disease, including MIGS devices, sustained release pharmaceutical implants, bio activated corneal crosslinking systems, transdermal formulations, and posterior segment drug delivery platforms.

Glaukos Corp holds a distinctive position in the ophthalmic medical technology and pharmaceutical sectors. In the glaucoma market, its MIGS offerings compete with products from Alcon (following its acquisition of Ivantis), Sight Sciences, and New World Medical, while its procedural pharmaceutical iDose TR faces competition principally from AbbVie. For corneal disorders, the company is the sole holder of an FDA approved bio activated pharmaceutical therapy for keratoconus, although it contends with various providers of corneal crosslinking procedures such as PeschkeTrade GmBH. Should its anterior segment pipeline receive regulatory approval, Glaukos Corp would encounter broader competition from large entities including AbbVie, Alcon, and Johnson & Johnson, and its posterior segment pipeline could be challenged by Novartis, Genentech/Roche, Regeneron Pharmaceuticals, and Bayer AG. The company emphasizes competitive advantages rooted in clinical superiority supported by extensive data, innovative features that improve patient benefit, product performance, and safety.

Glaukos Corp serves ophthalmic surgeons and other eye care professionals through a customer base that principally includes ambulatory surgery centers, hospitals, and physician private practices. The company does not disclose the names of individual customers, but it notes that no single customer or distributor accounted for more than ten percent of its total net sales in 2024, indicating a diversified client base across both domestic and international markets.